View Item 

Show simple item record

Valproate Protein Binding Is Highly Variable in ICU Patients and Not Predicted by Total Serum Concentrations: A Case Series and Literature Review
dc.contributor.authorRiker, Richard R.
dc.contributor.authorGagnon, David J.
dc.contributor.authorHatton, Colman
dc.contributor.authorMay, Teresa
dc.contributor.authorSeder, David B.
dc.contributor.authorStokem, Katie
dc.contributor.authorFraser, Gilles L.
dc.date.accessioned2017-04-14T15:11:47Z
dc.date.available2018-05-15T21:02:51Zen
dc.date.issued2017-04
dc.identifier.citationRiker, Richard R.; Gagnon, David J.; Hatton, Colman; May, Teresa; Seder, David B.; Stokem, Katie; Fraser, Gilles L. (2017). "Valproate Protein Binding Is Highly Variable in ICU Patients and Not Predicted by Total Serum Concentrations: A Case Series and Literature Review." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37(4): 500-508.
dc.identifier.issn0277-0008
dc.identifier.issn1875-9114
dc.identifier.urihttps://hdl.handle.net/2027.42/136503
dc.publisherWiley Periodicals, Inc.
dc.subject.otherintensive care
dc.subject.othertherapeutic drug monitoring
dc.subject.othervalproate
dc.subject.othervalproic acid
dc.subject.otherdivalproex
dc.subject.otheradverse drug effects
dc.subject.othermyoclonus
dc.subject.otherprotein binding
dc.subject.otherseizure
dc.titleValproate Protein Binding Is Highly Variable in ICU Patients and Not Predicted by Total Serum Concentrations: A Case Series and Literature Review
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136503/1/phar1912-sup-0001-SupInfo.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136503/2/phar1912_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136503/3/phar1912.pdf
dc.identifier.doi10.1002/phar.1912
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
dc.identifier.citedreferenceŠunjić KM, Webb AC, Šunjić I, Palà Creus M, Folse SL. Pharmacokinetic and other considerations for drug therapy during targeted temperature management. Crit Care Med 2015; 43: 2228 – 38.
dc.identifier.citedreferenceNavarro VJ, Senior JR. Drug‐related hepatotoxicity. N Engl J Med 2006; 354 ( 7 ): 731 – 9.
dc.identifier.citedreferenceWazny LD, Ariano RE. Evaluation and management of drug‐induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 2000; 20 ( 3 ): 292 – 307.
dc.identifier.citedreferenceBland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 327 ( 8476 ): 307 – 10.
dc.identifier.citedreferenceLevy RH. Monitoring of free valproic acid levels? Ther Drug Monit 1980; 2 ( 2 ): 199 – 201.
dc.identifier.citedreferenceGagnon DJ, Fontaine GV, Smith KE, et al. Valproate for agitation in critically ill patients: a retrospective study. J Crit Care 2016; 37: 119 – 25.
dc.identifier.citedreferenceAlvarez V, Januel JM, Burnand B, Rossetti AO. Second line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia 2011; 52 ( 7 ): 1292 – 6.
dc.identifier.citedreferenceMonsieurs KG, Nolan JP, Bossaerte LL, et al. European Resuscitation Council Guidelines for Resuscitation 2015 Section 1. Executive summary. Resuscitation 2015; 95: 1 – 80.
dc.identifier.citedreferenceOrr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, Godolphin W. Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects. Clin Pharmacol Ther 1982; 31: 642 – 9.
dc.identifier.citedreferenceBowdle AT, Patel IH, Levy RH, Wilensky AJ. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 1980; 28 ( 4 ): 486 – 92.
dc.identifier.citedreferenceHermida J, Tutor JC. A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients. J Pharmacol Sci 2005; 97: 489 – 93.
dc.identifier.citedreferenceKilpatrick CJ, Bury RW, Fullinfaw RO, et al. Plasma concentrations of unbound valproate and the management of epilepsy. Aust N Z J Med 1987; 17 ( 6 ): 574 – 9.
dc.identifier.citedreferenceFroscher W, Burr W, Penin H, Vohl J, Bülau P, Kreiten K. Free level monitoring of carbamazepine and valproic acid: clinical significance. Clin Neuropharmacol 1985; 8: 362 – 71.
dc.identifier.citedreferenceChan K, Beran RG. Value of therapeutic drug level monitoring and unbound (free) levels. Seizure 2008; 17 ( 6 ): 572 – 5.
dc.identifier.citedreferenceItoh H, Suzuki Y, Fujisaki K, Sato Y, Takeyama M. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy. Biol Pharm Bull 2012; 35 ( 6 ): 971 – 4.
dc.identifier.citedreferenceGidal B, Spencer N, Maly M, et al. Valproate‐mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 1994; 44 ( 8 ): 1418 – 22.
dc.identifier.citedreferenceRiker RR, Gagnon DJ, May T, Seder DB, Fraser GL. Analgesia, sedation, and neuromuscular blockade during targeted temperature management after cardiac arrest. Best Pract Res Clin Anaesthesiol 2015; 29 ( 4 ): 435 – 50.
dc.identifier.citedreferenceLevy RH, Moreland TA. Rationale for monitoring free drug levels. Clin Pharmacokinet 1984; 9 ( Suppl 1 ): 1 – 9.
dc.identifier.citedreferenceGibbs HG, Zimmerman DE, Shermock KM, Clarke W, Mirski MA, Lewin JJ 3rd. Comparison of free fraction serum valproic acid concentrations between inpatients and outpatients. Am J Health Syst Pharm 2015; 72 ( 2 ): 121 – 6.
dc.identifier.citedreferenceGugler R, Mueller G. Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol 1978; 5 ( 5 ): 441 – 6.
dc.identifier.citedreferencePatel IH, Levy RH. Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids. Epilepsia 1979; 20 ( 1 ): 85 – 90.
dc.identifier.citedreferenceZimmerman CL, Patel IH, Levy RH, Edwards D, Nelson SD, Hutchinson M. Protein binding of valproic acid in the presence of elevated free fatty acids in patient and normal human serum. Epilepsia 1981; 22 ( 1 ): 11 – 7.
dc.identifier.citedreferenceSandson NB, Marcucci C, Bourke DL, Smith‐Lamacchia R. An interaction between aspirin and valproate: the relevance of plasma protein displacement drug‐drug interactions. Am J Psychiatry 2006; 163 ( 11 ): 1891 – 6.
dc.identifier.citedreferenceLana F, Martí‐Bonany J, de Leon J. Ibuprofen may increase pharmacological action of valproate by displacing it from plasma proteins: a case report. Am J Psychiatry 2016; 173 ( 9 ): 941 – 2.
dc.identifier.citedreferenceLana F, Marti‐Bonany J, Fuster J, de Leon J. Reduction in serum concentration of valproic acid secondary to the intake of ibuprofen as an example of valproic acid auto‐induction metabolism. Actas Esp Psiquiatr 2016; 44: 136 – 44.
dc.identifier.citedreferenceBeran RG, Lewis JH, Nolte JL, Westwood AP. Use of total and free anticonvulsant serum levels in clinical practice. Clin Exp Neurol 1985; 21: 69 – 77.
dc.identifier.citedreferenceMayerhoff DI, Nurenberg J, Shah S, Schleifer SJ. Neurotoxicity associated with free valproic acid. Am J Psychiatry 2005; 162 ( 4 ): 810.
dc.identifier.citedreferenceXiong GL, Ferranti J, Leamon MH. Toxic interaction between valproate and oxcarbazepine: a case detected by the free valproate level. J Clin Psychopharmacol 2008; 28 ( 4 ): 472 – 3.
dc.identifier.citedreferencePatsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49 ( 7 ): 1239 – 76.
dc.identifier.citedreferenceAmerican Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1 – 50.
dc.identifier.citedreferenceZaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid—1988. Clin Pharmcokinet 1988; 15 ( 6 ): 367 – 89.
dc.identifier.citedreferenceHaroldson JA, Kramer LE, Wolff DL, Lake KD. Elevated free fractions of valproic acid in a heart transplant patient with hypoalbuminemia. Ann Pharmacother 2000; 34 ( 2 ): 183 – 7.
dc.identifier.citedreferenceLagneau F, Perbet S, Delefosse D, Wernet A, Stocco J, Marty J. Drugs pharmacokinetics in ICU patients: consequences of hypoalbuminemia upon drugs monitoring and dosing scheme. Intensive Care Med 2004; 30: 1247.
dc.identifier.citedreferencede Maat MM, van Leeuwen HJ, Edelbroek PM. High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy. Ann Pharmacother 2011; 45 ( 3 ): e18.
dc.identifier.citedreferenceJansen AJ, Hunfeld NG, van Bommel J, Koch BC, van Gelder T. Therapeutic drug monitoring of free fraction valproic acid in patients with hypoalbuminaemia. Neth J Med 2012; 70 ( 7 ): 329.
dc.identifier.citedreferenceClaassen J, Riviello JJ, Silbergleit R. Emergency neurological life support: status epilepticus. Neurocrit Care 2015; 23: S136 – 42.
dc.identifier.citedreferenceBrophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17: 3 – 23.
dc.identifier.citedreferenceTrinka E, Hӧfler J, Zerbs A, Brigo F. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs 2014; 28: 623 – 39.
dc.identifier.citedreferenceHaymond J, Ensom MH. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder? Ther Drug Monit 2010; 32: 19 – 29.
dc.identifier.citedreferenceHiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44 ( 6 ): 195 – 235.
dc.identifier.citedreferenceParent X, Marzullo C, Gutbub AM. Acide valproïque: estimation simple de la concentration sérique libre. Ann Biol Clin (Paris) 1993; 51: 649 – 50.
dc.identifier.citedreferenceLampon N, Tutor JC. Apparent clearance of valproic acid in elderly epileptic patients: estimation of the confounding effect of albumin concentration. Upsala J Med Sci 2012; 117: 41 – 6.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phar1912-sup-0001-SupInfo.pdf
Size:
261.8KB
Format:
PDF
View/Open
Name:
phar1912_am.pdf
Size:
306.8KB
Format:
PDF
View/Open
Name:
phar1912.pdf
Size:
242.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.